Born and raised in Los Angeles, she has since lived in different parts of the United States as she pursued graduate training at both the University of Michigan and the University of Pittsburgh. While at the University of Pittsburgh, she contributed to the identification and validation of new therapeutic targets in adult and pediatric high-grade gliomas, and in breast cancer, ovarian cancer, and pancreatic cancer. Outside of work, she enjoys exploring the city’s vibrant food scene, adventuring outdoors, hosting board game nights, and spending time with friends and family.

Alethea Wieland, President and Founder remarks, “We are excited for Andrea to transition from academia to industry, and she had a great head start working with CRS previously as an intern, including performing a gap analysis on ICH GCP E6R2 to R3 – a project that can seem intimidating to most. She collaborated with teammates and demonstrated nothing is too big or too small to tackle.”

David Link, MBA, CRS CEO and Chief Quality and Regulatory Officer adds, “Dr. Cruz brings poise to her new role as Project Lead at CRS and her background in cellular and molecular pathology dovetails nicely with our high-impact precision medicine clients.”

About Clinical Research Strategies, LLC:

CRS is a specialty clinical CRO and executive management consulting firm that fits-for-purpose veteran life sciences executives, attorneys, regulatory scientists and strategists, clinical operations, project management, quality assurance engineers, and sales and marketing teams to take on the biggest challenges for start-up, mid-sized, and large life sciences companies, many of whom are developing novel, first-in-class drugs, biologics, diagnostics and medical devices, or software as a medical device (SaMD). Service areas are clinical trials, Functional Service Provider (FSP) models, selection and management of CROs, regulatory compliance strategy and submissions, QMS, EU MDR and GDPR, rescue trials, TMF, risk mitigation and remediation, training high-performing teams, staffing solutions, and decentralized trials.

Indications represented are Aging, Biosensors, Cannabis, Cardiovascular Disease, Central Nervous System, Critical Care Medicine, Gastroenterology, Genetics, Infectious Disease, Immunology, Men’s Health, Metabolic Disorders, Microbiome, Neonates & Pediatrics, Neurology, Oncology, Ophthalmology, Opioid Abuse, Orthopedics, Pain, Precision Medicine, Rare Diseases, Radiology, Regenerative Medicine, Respiratory Diseases, Sleep, Women’s Health, Wound-Healing.

CRS is an approved sub-contractor for the NIH, DoD and DARPA. CRS is affiliated with MTEC and is a Spoke Member of ARPA-H.

CRS requires persons to be authorized to work in the United States and to undergo a background check prior to becoming employed. CRS is an inclusive employer and does not discriminate in employment on the basis of race, color, religion, sex, gender identity, national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, education, membership in an employee organization, parental status, military service, vaccine status, or other non-merit factor. CRS does not tolerate censorship, surveillance, bullying, intimidation, retaliation, discrimination, or harassment of any kind.

# # #

Media Contact:
Ron MacDonald
Step2 Branding and Design
ro****@***********ng.com
+1 724.814.4067

Alethea Wieland, President and Founder
Clinical Research Strategies, LLC
al*****@************************es.com
+1 724.272.1245

Download this press release as a PDF.